NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• Acute myeloid leukemia (AML) accounts for nearly 30% of all AML cases and is associated with internal tandem duplications (ITDs) in the FMS-like tyrosine kinase 3 receptor (FLT3).
• FLT3-ITD mutations are linked to a poor prognosis in AML patients.
• MicroRNAs (miRNAs) play a crucial role in myeloid differentiation and the development of leukemia.

Purpose of the Study:

• To investigate the role of microRNA-155 (miR-155) in FLT3-ITD-associated AML.
• To elucidate the regulatory network connecting FLT3-ITD signaling, miR-155, and downstream targets.

Main Methods:

• In vitro and in vivo experiments were conducted to study miR-155 expression.
• Investigated the regulation of miR-155 by FLT3-ITD downstream targets, including nuclear factor-κB (p65) and signal transducer and activator of transcription 5 (STAT5).
• Assessed the effect of miR-155 on the myeloid transcription factor PU.1 and its impact on leukemic cell proliferation and apoptosis.

Main Results:

• FLT3-ITD signaling was found to induce the expression of oncogenic miR-155.
• miR-155 expression is regulated by p65 and STAT5, downstream targets of FLT3-ITD.
• miR-155 directly targets the transcription factor PU.1, and its knockdown or PU.1 overexpression inhibits proliferation and induces apoptosis in FLT3-ITD-associated AML cells.

Conclusions:

• FLT3-ITD signaling establishes a novel oncogenic network in AML by inducing miR-155 through p65 and STAT5.
• This network leads to the targeting of PU.1 by miR-155, contributing to leukemic cell survival and proliferation.
• Targeting this miR-155/PU.1 axis presents a potential therapeutic strategy for FLT3-ITD-mutated AML.